RxDoctor Payments Data

Adnan Bhopalwala, MD

Cardiovascular Disease · Whitesburg, KYNPI 1811200744

Payments from drug & device makers

$1,150in general payments, 2019–2025

Across 78 payments — averaging $14.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$239
  • Pfizer$191
  • Novartis$168
  • Boston Scientific$140
  • Merck$119
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$68
  • plus $225 from 7 others

What the payments were for

  • Food & beverage$1,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,150 in reported general payments places this provider in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$92,928
Medicare patients
737
Services billed
1,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban343$265,516
EntrestoSacubitril/Valsartan193$156,611
FarxigaDapagliflozin Propanediol104$79,099
XareltoRivaroxaban64$56,127
VerquvoVericiguat16$16,247
Praluent PenAlirocumab19$14,745
JardianceEmpagliflozin18$11,851
CorlanorIvabradine Hcl12$7,377
Metoprolol Succinate719$6,204
Atorvastatin Calcium334$2,340
Diltiazem 24hr Er (Cd)Diltiazem Hcl164$2,284
Isosorbide Mononitrate ErIsosorbide Mononitrate250$1,999
VascepaIcosapent Ethyl11$1,917
Amiodarone Hcl161$1,886
Bumetanide75$1,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$191$265,516343 claims
NovartisEntresto$168$156,611193 claims
AstraZenecaFarxiga$239$79,099104 claims
MerckVerquvo$119$16,24716 claims
Boehringer IngelheimJardiance$12$11,85118 claims
AmgenCorlanor$35$7,37712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Whitesburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →